Home > List All Publishers > CBR Pharma Insights, LLC

CBR Pharma Insights, LLC

The mission of CBR Pharma Insights is to empower companies within the pharmaceutical industry to make the best business decisions possible through providing them with quality, innovative, strategic market research solutions.

CBR’s market research solutions are focused on being both proactive & reactive in identifying, evaluating, and assessing the key strategic R&D and commercial issues within the pharmaceutical industry.

List of reports from CBR Pharma Insights, LLC

The Politics of Pharma (CBRSV042) – Washington, States, and the Courts Impact on the Industry 4/1/2013 \| published by: CBR Pharma Insights, LLC ... same, with the re-election of President Obama, Democratic control of the Senate and Republican control of the House. However, the outcome of the elections will still impact the industry in a variety of ways. The ... \| read more...	$3,900.00
R&D Productivity – The State of Research and Development in the BioPharmaceutical Industry (CBRSV043) 4/1/2013 \| published by: CBR Pharma Insights, LLC ... from? Is spend decreasing? If spend is decreasing, what impact is this having on R&D? What can be done to encourage innovation in the biotech and pharmaceutical industry? Is the biotech model of R&D better ... \| read more...	$3,900.00
Biopharma M&A and Deal Making (CBRSV041) – Understanding the Latest Trends to Optimize Future Strategy 3/1/2013 \| published by: CBR Pharma Insights, LLC ... while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is ... \| read more...	$3,900.00
Electronic Health Records – Charting the Future of Health Care (CBRSV040) 1/1/2013 \| published by: CBR Pharma Insights, LLC ... the goal of having every American covered by an EHR within 10 years. In 2009, President Obama added the key element of funding under the American Recovery and Reinvestment Act. The EHR Meaningful Use Incentive ... \| read more...	$3,900.00
Oncology Development Strategies – Considerable Commercial Potential but Specific Needs Must Be Addressed 1/1/2013 \| published by: CBR Pharma Insights, LLC ... drugs that get to Phase III proceeding to approval. There are a number of factors that will affect the likelihood of success in oncology drug development and these must be taken into consideration when designing ... \| read more...	$3,900.00
The Digital Patient – A Snapshot of the Digital Landscape of Patients and Caregivers 11/1/2012 \| published by: CBR Pharma Insights, LLC ... patients and caregivers have pre-existing expectations of the digital experience. Digital enables brands to deliver highly targeted information in a variety of forms. It creates the setting for a brand experience versus a promotional moment. ... \| read more...	$3,900.00
Biologics in the Emerging Markets – Ripe for Realization of the Commercial Potential – But Hurdles Still to Overcome 9/1/2012 \| published by: CBR Pharma Insights, LLC ... many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010. Of the emerging markets, the BRIC markets offer the greatest potential ... \| read more...	$3,900.00
Emerging Pharmaceutical Technologies – Stem Cells 8/1/2012 \| published by: CBR Pharma Insights, LLC ... largely unproven at present. Even if companies are not interested in joining the first wave of stem cell therapy developers, they need to be monitoring this sector in order to understand future competitive threats. The ... \| read more...	$3,900.00
Accountable Care Organizations – A Building Block for the Future of Health Care 8/1/2012 \| published by: CBR Pharma Insights, LLC ... is the Medicare Shared Savings Program, under which ACOs gradually share in the cost savings they achieve through providing coordinated and consistent care to groups of Medicare beneficiaries while meeting quality targets. The focus of ... \| read more...	$3,900.00
Clinical Development and Trial Design – Developing a Coherent Approach from Beginning to End 6/1/2012 \| published by: CBR Pharma Insights, LLC ... streamlined process throughout. The clinical development plan ties together all aspects of product development, enabling an incorporated approach to the clinical and commercial rationale of product development. A variety of approaches should be adopted to ... \| read more...	$3,900.00
Diversification in the Pharmaceutical Industry – Essential For Survival or an Unnecessary Distraction? 5/1/2012 \| published by: CBR Pharma Insights, LLC ... remains split on whether diversification or specialization is the key to building a successful business model in the face of these difficulties. On one hand some companies believe that diversification is necessary to survive and ... \| read more...	$3,900.00
The Payer Landscape in the United States – The Pharmaceutical Industry Faces a Rapidly Changing Marketplace 3/1/2012 \| published by: CBR Pharma Insights, LLC ... 2010 providing changes for both. That said, private payers, such as regionals, nationals and blues plans, may take the brunt of the reform policies put in place. The health care reform legislation in 2010 was ... \| read more...	$3,900.00
The Next Generation of Pharmaceutical Marketing Strategies – Understanding All of the Strategic Considerations Needed in the Age of Multiple Stakeholders 3/1/2012 \| published by: CBR Pharma Insights, LLC ... a period of great transformation. Lacking a crystal ball, the industry as a whole is navigating through unchartered waters. Multiple factors are driving the need for industry-wide change. One of the biggest contributors is the ... \| read more...	$3,900.00
Pharmaceutical Pricing Strategies – Changing Approaches to Meet Challenging Times 3/1/2012 \| published by: CBR Pharma Insights, LLC ... discounts forced upon them and new drugs being subject to increasingly complex assessments in order to obtain the desired price. Novel pricing policies, such as value based pricing and external price referencing, are being employed ... \| read more...	$3,900.00
Reformulation Strategies – New Technologies Extend Use Beyond Lifecycle Management 1/1/2012 \| published by: CBR Pharma Insights, LLC ... new technologies emerge compliment its position as a key lifecycle management strategy. Reformulation will continue to be a much used lifecycle management strategy, enabling companies to boost sales before patent expiry and in ideal cases ... \| read more...	$3,900.00
Looking at Senior Long-term Care - Where Will the Market Go? P 12/1/2011 \| published by: CBR Pharma Insights, LLC ... Skilled Nursing. Memory Care facilities, for those with Alzheimer’s Disease or Dementia are often separate facilities, but may be part of a larger CCRC campus. Long-term care is becoming increasingly important as a market with ... \| read more...	$3,900.00
The Impact of Generics on Pharmaceutical Growth Opportunities - A growing threat that offers future opportunities 10/1/2011 \| published by: CBR Pharma Insights, LLC ... this, pharma is experiencing a wave of blockbuster patent expiries, with almost $30 billion in US sales (at 2010 levels) exposed by the largest 10 drugs which are expected to experience generic competition for the ... \| read more...	$3,900.00
Risk Evaluation and Mitigation Strategies - Adaptation in an Evolving System 10/1/2011 \| published by: CBR Pharma Insights, LLC ... (REMS) program in 2008. Products can be approved with a Medication Guide only REMS, a Communication Plan REMS - which incorporates a Medication Guide together with educational materials for providers or it can require Elements ... \| read more...	$3,900.00
Accelerating Drugs to Market - In Search of Opportunity Along the Drug Development & Approval Pathway 9/1/2011 \| published by: CBR Pharma Insights, LLC ... gain competitive advantages and to start recouping development costs. From product concept to market, there are a number of potential areas of opportunity for accelerating a drug through to FDA approval. Many initiatives tie to ... \| read more...	$3,900.00
Pharmaceutical Sales Force Effectiveness - Rethinking the Current Sales Model 8/1/2011 \| published by: CBR Pharma Insights, LLC ... to this mix Health Care Reform and the way a company develops, markets, and sells their products is impacted on some level. The next 5 - 10 years will be an exciting time to be ... \| read more...	$3,900.00
Pharmaceutical Cliff Diving - Assessing the Key Challenges that will Re-Shape the Industry 7/1/2011 \| published by: CBR Pharma Insights, LLC ... big pharma, sales were flat to negative for most, but a number of companies found that their work to streamline and restructure were showing positive results, with Q1 profits up. The industry faces challenges from ... \| read more...	$3,900.00
The Coming Age of Biosimilars - Regulatory Developments and Alliance Strategies Intensify Interest in a Developing Market 5/1/2011 \| published by: CBR Pharma Insights, LLC ... predicting it will grow to the multi-billion dollar level within five years, while others point to the limited impact of biosimilars in Europe to date to suggest that it will never be a major threat ... \| read more...	$3,900.00
New Product Launch Strategies - Initiating Market Entry with Sound Strategies and Tactics 4/1/2011 \| published by: CBR Pharma Insights, LLC ... growth; however lost opportunities at the entry of a product to a market can necessitate re- launch and re-branding activities which can be costly and cumbersome. Additionally, these “Plan B” tactics are not always effective. ... \| read more...	$3,900.00
The Impact of Economic Factors on the Pharmaceutical Industry - Where the Next Five Years Will Take Us 3/1/2011 \| published by: CBR Pharma Insights, LLC ... we’re currently in has brought a number of challenges for the pharmaceutical industry, such as loss of health coverage through unemployment, decreasing health benefits for those still employed, and a lessened ability to pay for ... \| read more...	$3,900.00
Pharmaceutical and Biotech Licensing Strategies - Driving Revenue through Partnerships 1/1/2011 \| published by: CBR Pharma Insights, LLC ... one grounded in collaboration. Companies are no longer relying solely on their own internal R&D programs for innovation; they are looking outside of their four walls. Some have labeled this ‘search and development’. There are ... \| read more...	$3,900.00

< prev 1 2 next >